trial

A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia

NCTId NCT00888693
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 81 (actual)
Sponsored by AbbVie
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
81 (actual)
Study type
Interventional
Allocation
Randomized
Model
Single Group
Masking
Double
Start
2008-11
Primary completion
2009-12
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
ABT-288

Sponsors

AbbVieLead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
81
Phase
PHASE1
Primary Completion Date
2009-12
Status
COMPLETED
relationships
The graph out of here
drug
ABT-288
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia
indication